用激肽释放酶治疗男性生育力低下

The treatment of male subfertility with kallikrein.

作者信息

Izzo P L, Canale D, Bianchi B, Meschini P, Esposito G, Menchini Fabris G F, Fasani R, Ohnmeiss H

出版信息

Andrologia. 1984 Mar-Apr;16(2):156-61. doi: 10.1111/j.1439-0272.1984.tb00256.x.

DOI:10.1111/j.1439-0272.1984.tb00256.x

Abstract

In a controlled double blind trial the effectiveness and tolerability of Kallikrein in patients suffering from astheno-oligozoospermia was examined in comparison to placebo. 30 patients with astheno-oligozoospermia of idiopathic origin entered the study; they were subdivided into two homogeneous groups of 15 patients each. Group A was treated with 600 K.U. daily for 3 months, group B received placebo tablets. In the Kallikrein group all parameters improved, as sperm motility, volume of semen, sperm concentration, total sperm value, and rate of normal spermatozoa. No changes of endocrinological findings were observed. Three pregnancies occurred in this group. No conceptions were observed in the wives of those patients treated with placebo (group B). Tolerability was very good in all patients.

摘要

在一项对照双盲试验中，研究了激肽释放酶与安慰剂相比，对患有弱精子症和少精子症患者的有效性和耐受性。30名特发性弱精子症和少精子症患者进入研究；他们被分为两组，每组15名患者。A组每天接受600国际单位治疗，持续3个月，B组接受安慰剂片。在激肽释放酶组中，所有参数均有所改善，如精子活力、精液量、精子浓度、总精子值和正常精子率。未观察到内分泌结果的变化。该组有3例妊娠。接受安慰剂治疗的患者（B组）的妻子未观察到受孕情况。所有患者的耐受性都非常好。